Skip to main content
Premium Trial:

Request an Annual Quote

HTG, Merck KGaA Ink CDx Development Deal for Lymphoma Drug

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics announced yesterday that it has signed a master companion diagnostics development agreement with Merck KGaA, which will initially focus on a test for use with the German drugmaker's investigational Bruton's tyrosine kinase (BTK) inhibitor M7583.

BTK is an enzyme associated with B cell development and implicated in certain autoimmune diseases and cancers. Merck is developing M7583 as a treatment for B cell lymphoma and expects to begin clinical testing of the drug this year.

Under the terms of their deal, the companies will develop a companion diagnostic for M7583 based on HTG's EdgeSeq Diffuse Large B-Cell Lymphoma (DLBCL) Cell of Origin Assay, which uses next-generation sequencing-based gene expression profiling to determine the cell of origin subtype of DLBCL tumors. The assay received CE IVD marking earlier this year. Additional development programs may follow, according to TJ Johnson, HTG’s President and CEO.

Further terms of the agreement were not disclosed.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.